📊 MTVA Key Takeaways
Is MTVA a Good Investment? Thesis Analysis
MetaVia is a pre-commercial pharmaceutical company in severe financial distress, with annual revenue of only $510K against operating losses of $13.7M and negative free cash flow of -$15.7M. The company faces less than one year of cash runway at current burn rates, compounded by accelerating revenue decline (-44.6% YoY), making near-term capital infusion or dramatic revenue acceleration essential for survival.
Why Buy MTVA? Key Strengths
- Cash position of $10.3M provides minimal operational runway
- Year-over-year improvement in net income losses (+53%) and diluted EPS (+81.2%) suggests operational adjustments
- Zero long-term debt eliminates refinancing risk
MTVA Investment Risks to Consider
- Catastrophic revenue base of $510K annually is insufficient to support operations
- Operating cash burn of -$15.7M annually will deplete cash reserves within 6-9 months
- Revenue declining sharply at -44.6% YoY, signaling deteriorating commercial viability
- Operating and net margins of -2687.8% and -2543.7% demonstrate fundamentally broken business model
- No visible path to profitability with current asset base and losses exceeding 26x annual revenue
Key Metrics to Watch
- Quarterly revenue run-rate and new product pipeline announcements
- Monthly cash burn rate and months of cash runway remaining
- Capital raising activities or strategic partnerships
MTVA Financial Metrics
💡 AI Analyst Insight
MetaVia Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MTVA Profitability Ratios
MTVA vs Healthcare Sector
How MetaVia Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MTVA Overvalued or Undervalued?
Based on fundamental analysis, MetaVia Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MTVA Balance Sheet & Liquidity
MTVA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MetaVia Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-39.13 indicates the company is currently unprofitable.
MTVA Growth Metrics (YoY)
MTVA Capital Allocation
MTVA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MetaVia Inc. (CIK: 0001638287)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MTVA
What is the AI rating for MTVA?
MetaVia Inc. (MTVA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MTVA's key strengths?
Claude: Cash position of $10.3M provides minimal operational runway. Year-over-year improvement in net income losses (+53%) and diluted EPS (+81.2%) suggests operational adjustments.
What are the risks of investing in MTVA?
Claude: Catastrophic revenue base of $510K annually is insufficient to support operations. Operating cash burn of -$15.7M annually will deplete cash reserves within 6-9 months.
What is MTVA's revenue and growth?
MetaVia Inc. reported revenue of $510.0K.
Does MTVA pay dividends?
MetaVia Inc. does not currently pay dividends.
Where can I find MTVA SEC filings?
Official SEC filings for MetaVia Inc. (CIK: 0001638287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MTVA's EPS?
MetaVia Inc. has a diluted EPS of $-7.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MTVA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MetaVia Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MTVA stock overvalued or undervalued?
Valuation metrics for MTVA: ROE of -243.3% (sector avg: 15%), net margin of -2,543.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MTVA stock in 2026?
Our dual AI analysis gives MetaVia Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MTVA's free cash flow?
MetaVia Inc.'s operating cash flow is $-15.7M, with capital expenditures of $2.0K. FCF margin is -3,079.0%.
How does MTVA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,543.7% (avg: 12%), ROE -243.3% (avg: 15%), current ratio 1.93 (avg: 2).